Publication Name	World Journal of Clinical Cases
Manuscript ID	77540
Country	China

Received	2022-05-31 15:09
Peer-Review Started	2022-05-31 15:13
To Make the First Decision
Return for Revision	2022-07-14 08:24
Revised	2022-08-01 15:23
Second Decision	2022-09-20 03:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-09-21 00:15
Articles in Press	2022-09-21 00:15
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-09-18 09:51
Typeset the Manuscript	2022-10-18 07:06
Publish the Manuscript Online	2022-10-27 04:55

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pediatrics
Manuscript Type	Clinical Trials Study
Article Title	Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study
Manuscript Source	Unsolicited Manuscript
All Author List	Tong-Tong Cao, Li Chen, Xiao-Fang Zhen, Gao-Jie Zhao, Hui-Fang Zhang and Yan Hu
ORCID	Author(s) ORCID Number Yan Hu http://orcid.org/0000-0003-1255-6797
Funding Agency and Grant Number	Funding Agency Grant Number Capital Health Research and Development of Special No. CH2018-2-2092
Corresponding Author	Yan Hu, MD, PhD, Director, Director, Doctor, Doctor, Department of Traditional Chinese Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nanlishi Road, Beijing 100045, China. huyan13370115073@163.com
Key Words	Lupus nephritis; Traditional Chinese medicine; Dan Bai Xiao Formula; Effective; Safe
Core Tip	Lupus nephritis (LN) is the most common and serious complication of systemic lupus erythematosus. Glucocorticoids (GCs) and immunosuppressants were considered routine treatments for patients with LN. However, there is a widespread consensus regarding the toxicity of immunosuppressive agents and the necessity of preventing children from taking these medications over an extended period. Accordingly, there is an increasing need for holistic and optimal therapy that results in a higher rate of remission and fewer side effects. Our study suggests that Dan Bai Xiao Formula (DBXF) treatment is effective and safe as a supplementary therapy for LN; moreover, this treatment is superior to routine GC and cyclophosphamide therapies. DBXF containing combination treatment may lead to faster proteinuria and hematuria resolution, smoother GC reduction, fewer methylprednisolone pulses, and fewer adverse events.
Publish Date	2022-10-27 04:55
Citation	Cao TT, Chen L, Zhen XF, Zhao GJ, Zhang HF, Hu Y. Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study. World J Clin Cases 2022; 10(31): 11391-11402
URL	https://www.wjgnet.com/2307-8960/full/v10/i31/11391.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i31.11391

Full Article (PDF)	WJCC-10-11391.pdf
Full Article (Word)	WJCC-10-11391.docx
CONSORT 2010 Statement	77540-CONSORT-2010-Statement-revision.pdf
Manuscript File	77540_Auto_Edited-YLC-Wang TQ-JLW.docx
Answering Reviewers	77540-Answering reviewers.pdf
Audio Core Tip	77540-Audio core tip.wav
Biostatistics Review Certificate	77540-Biostatistics statement.pdf
Clinical Trial Registration Statement	77540-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	77540-Conflict-of-interest statement.pdf
Copyright License Agreement	77540-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	77540-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	77540-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	77540-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	77540-Language certificate.pdf
Peer-review Report	77540-Peer-review(s).pdf
Scientific Misconduct Check	77540-Bing-Chen YL-2.png
Scientific Editor Work List	77540-Scientific editor work list.pdf
CrossCheck Report	77540-CrossCheck report.pdf